Loading stock data…
DexCom, Inc. (DXCM)
$84.03-0.50 (-0.59%)
Market OpenUpdated 2:27 PM EDT
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DexCom, Inc. in the Healthcare sector is trading at $84.03 with a market capitalization of $33.1B. Wall Street consensus targets $94.12 (25 analysts), implying a +12.0% move over the next 12 months. The stock is currently 9% below its 52-week high of $92.59, remaining 18.1% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +12.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 31) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.31B↑ | $1.19B↓ | $1.26B↑ | $1.21B↑ | $1.16B |
| Gross Profit | $830.00M↑ | $750.30M↓ | $792.70M↑ | $731.40M↑ | $688.80M |
| Operating Income | $318.30M↑ | $255.30M↓ | $323.00M↑ | $242.50M↑ | $212.60M |
| Net Income | $249.10M↑ | $199.50M↓ | $267.30M↓ | $283.80M↑ | $179.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$33.08B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
33.45
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.41
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
38.14%
Volume
Today's trading volume
1.80M
Recent News
DexCom Stock: Is DXCM Underperforming the Healthcare Sector?
DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.
DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair
DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sits meaningfully above the current market price. At the same time, broader valuation checks lean cautious and market based multiples look roughly in line with peers rather than clearly cheap. Over the past five years, DexCom shareholders have seen the stock decline about 35.1%, which puts more...
Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services
Reviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.
3 Reasons DXCM Has Explosive Upside Potential
Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.